AlphaYou
Overview
Key stats
Fundamentals Sep 12- Open
- $145.52
- 52-wk high
- $156.92
- High
- $145.90
- 52-wk low
- $75.81
- Low
- $143.68
- Prev close
- $144.71
- Mkt cap
- $355.10B
- P/E
- 116.1x
- Volume
- 8.68M
- Fwd P/E
- 14.9x
- Beta
- 0.23
- Div yield
- 2.29%
- P/S
- 5.3x
- P/B
- 8.5x
- Profit margin
- +4.8%
- Op margin
- -0.2%
- ROE
- +7.0%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsSmart money
8 funds hold a position and insiders have been net selling.
What funds are doing
Activist stakes, short interest & more
Earnings
Earnings came in 50.0% above what analysts expected.
Earnings per share
-$0.26 expected
Full Year 2026 guidance
$66.30B to $67.30B
No comparable estimate
Reports Oct 29, 2026, in 46 days
EPS expected
$2.01 to $2.41
Revenue expected
16 analysts
Last 30 days
Analysts cutting estimates
Estimate drift
Change in 30 days
What the company said
Financials
What it sold, what it cost, what was left.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $17.18B | $16.32B | $16.29B | $16.61B |
| Cost of what it sold | $4.19B | $4.82B | $2.94B | $4.39B |
| Gross profit | $12.99B | $11.51B | $13.34B | $12.21B |
| What it spent | ||||
| Research and development | $3.55B | $2.50B | $12.56B | $9.74B |
| Sales and admin | $2.63B | $2.85B | $2.70B | $2.90B |
| Other operating costs | -$659.0M | — | — | $250.0M |
| Total operating expenses | $5.53B | $5.35B | $15.23B | $12.89B |
| What was left | ||||
| Operating profit | $7.46B | $6.16B | -$1.88B | -$683.0M |
| Interest on debt | $327.0M | $411.0M | $479.0M | $525.0M |
| Profit before tax | $6.75B | $3.42B | -$3.53B | -$683.0M |
| Tax | $958.0M | $458.0M | $709.0M | $654.0M |
| Net profit | $5.79B | $2.96B | -$4.24B | -$1.33B |
| EBITDA | $8.14B | $6.30B | -$2.02B | $1.43B |
Technicals
Price structure
This stock is trending upward.
Trend
Constructive
65 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
News
What the news says
Coverage is bullish
Tone of tracked coverage
IPG Investment Advisors LLC Lowers Position in Merck & Co., Inc. $MRK
NeutralSep 11Rep. Maria Elvira Salazar Acquires Shares of Moderna, Inc. (NASDAQ:MRNA)
NeutralSep 11Rep. Maria Elvira Salazar Sells Moderna, Inc. (NASDAQ:MRNA) Stock
NeutralSep 11Rep. Maria Elvira Salazar Buys Merck & Co., Inc. (NYSE:MRK) Stock
Leans bullishSep 11Merck & Co., Inc. (NYSE:MRK) Trading Down 1.9% - Should You Sell?
NeutralSep 10Merck (MRK) Dips More Than Broader Market: What You Should Know
Leans bearishSep 10Maria Elvira Salazar makes significant trades in Berkshire Hathaway and Chubb Limited stocks
Leans bullishSep 10Arcus Biosciences at cantor global healthcare conference: casdatifan in focus By Investing.com
NeutralSep 10
Macro
22 macro signals shaping MRK right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results